| Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V M Colleoni, Z Sun, KN Price, P Karlsson, JF Forbes, B Thürlimann, ... Journal of clinical oncology 34 (9), 927, 2016 | 602 | 2016 |
| Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. I Panzini, L Gianni, PP Fattori, D Tassinari, M Imola, P Fabbri, V Arcangeli, ... Tumori 88 (1), 21-27, 2002 | 326 | 2002 |
| Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients G Visani, C Finelli, U Castelli, MC Petti, P Ricci, N Vianelli, L Gianni, ... British journal of haematology 75 (1), 4-9, 1990 | 251 | 1990 |
| Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label … D Amadori, M Aglietta, B Alessi, L Gianni, T Ibrahim, G Farina, F Gaion, ... The Lancet Oncology 14 (7), 663-670, 2013 | 201 | 2013 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 170 | 2022 |
| Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial International Breast Cancer Study Group (IBCSG) Journal of the National Cancer Institute 94 (14), 1054-1065, 2002 | 148 | 2002 |
| Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial … G Pruneri, KP Gray, A Vingiani, G Viale, G Curigliano, C Criscitiello, ... Breast cancer research and treatment 158 (2), 323-331, 2016 | 124 | 2016 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 112 | 2018 |
| Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2 … M Pestrin, S Bessi, F Puglisi, AM Minisini, G Masci, N Battelli, A Ravaioli, ... Breast cancer research and treatment 134, 283-289, 2012 | 110 | 2012 |
| The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study D Samorani, T Fogacci, I Panzini, G Frisoni, FG Accardi, M Ricci, E Fabbri, ... European Journal of Surgical Oncology (EJSO) 41 (1), 64-70, 2015 | 97 | 2015 |
| Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: Long-term follow-up of the BIG 1-98 trial T Ruhstaller, A Giobbie-Hurder, M Colleoni, MB Jensen, B Ejlertsen, ... Journal of clinical oncology 37 (2), 105-114, 2019 | 93 | 2019 |
| Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial O Nanni, D Amadori, A De Censi, A Rocca, A Freschi, A Bologna, ... Breast cancer research and treatment 174, 433-442, 2019 | 87 | 2019 |
| Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor–negative early breast cancer: international breast cancer study group trial 22-00 M Colleoni, KP Gray, S Gelber, I Láng, B Thürlimann, L Gianni, EA Abdi, ... Journal of clinical oncology 34 (28), 3400, 2016 | 81 | 2016 |
| Acute disseminated intravascular coagulation syndrome in cancer patients E Pasquini, L Gianni, E Aitini, M Nicolini, PP Fattori, G Cavazzini, ... Oncology 52 (6), 505-508, 1995 | 81 | 1995 |
| Hypercoagulability during l‐asparaginase treatment: the effect of antithrombin III supplementation in vivo L Gugliotta, A D'Angelo, MM Belmonte, S Viganò‐D'Angelo, G Colombo, ... British journal of haematology 74 (4), 465-470, 1990 | 79 | 1990 |
| HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer A Volpi, O Nanni, F De Paola, AM Granato, A Mangia, F Monti, F Schittulli, ... Journal of clinical oncology 21 (14), 2708-2712, 2003 | 74 | 2003 |
| Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials L Gianni, I Panzini, S Li, RD Gelber, J Collins, SB Holmberg, D Crivellari, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 69 | 2006 |
| Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: the CASA … D Crivellari, KP Gray, S Dellapasqua, F Puglisi, K Ribi, KN Price, I Láng, ... The Breast 22 (2), 130-137, 2013 | 66 | 2013 |
| Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma S Cortelazzo, A Rossi, E Roggero, E Oldani, E Zucca, C Tondini, ... Annals of Oncology 10 (12), 1433-1440, 1999 | 65 | 1999 |
| Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer L Gianni, I Panzini, D Tassinari, AM Mianulli, F Desiderio, A Ravaioli Annals of Oncology 12 (8), 1178-1178, 2001 | 64 | 2001 |
